Previous 10 | Next 10 |
2023-11-19 09:52:24 ET Summary Today, we revisit CymaBay Therapeutics, a clinical stage biopharma company focused on developing therapies for liver and chronic diseases. The company's primary product candidate, seladelpar, has shown positive results in treating primary biliary cho...
2023-11-13 20:41:53 ET More on Genfit Genfit GAAP EPS of -€0.42, revenue of €15.37M Seeking Alpha’s Quant Rating on Genfit Historical earnings data for Genfit Financial information for Genfit For further details see: Genfit st...
2023-11-13 18:01:34 ET Gainers: Theseus Pharmaceuticals ( THRX ) +35% . GENFIT ( GNFT ) +15% . Lifeway Foods ( LWAY ) +9% . Digital World Acquisition ( DWACW ) +8% . Digital World Acquisition ( DWAC ) +5% . Lose...
2023-09-20 16:21:53 ET More on Genfit Seeking Alpha’s Quant Rating on Genfit Historical earnings data for Genfit Financial information for Genfit Genfit gains as Phase 3 trial for liver disease candidate succeeds (update) For further details se...
2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...
2023-09-07 07:56:40 ET More on CymaBay Seeking Alpha’s Quant Rating on CymaBay Therapeutics Historical earnings data for CymaBay Therapeutics Financial information for CymaBay Therapeutics CymaBay Therapeutics, Inc. ( CBAY ) Q2 2023 Earnings Call...
2023-08-14 16:31:43 ET UBS has initiated coverage of Cymabay Therapeutics ( NASDAQ: CBAY ) with a buy rating, stating it sees a Phase 3 study for the company’s drug seladelpar in the treatment of primary biliary cholangitis, or PBC, yielding positive data. UBS said it exp...
2023-07-13 08:04:34 ET Intercept Pharmaceuticals ( NASDAQ: ICPT ) gained ~10% pre-market Thursday after H.C. Wainwright upgraded it to Buy from Sell, citing a novel drug combination the company is developing for an autoimmune disease called primary biliary cholangitis (PBC). ...
2023-07-03 08:41:08 ET PainReform ( PRFX ) +22% . Alvotech ( ALVO ) +19% . Ensysce Biosciences ( ENSC ) +12% . Alliance Entertainment ( AENT ) +10% . Great Ajax AJX +9% on plans to be acquired by Ellington Financial for $7.33...
2023-06-30 06:58:14 ET French biotech Genfit S.A. ( NASDAQ: GNFT ) added ~23% pre-market Friday after the company and its partner Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) announced that a Phase 3 trial for elafibranor targeted at the rare liver disease primary biliary chola...
News, Short Squeeze, Breakout and More Instantly...
GENFIT S.A. Company Name:
GNFT Stock Symbol:
NYSE Market:
Lakeland Industries Inc. (LAKE) is expected to report $0.3 for Q4 2024 Sekisui House Ltd. ADR (SKHSY) is expected to report for Q4 2024 Hingham Institution for Savings (HIFS) is expected to report for Q1 2024 GENFIT S.A. (GNFT) is expected to report for Q4 2023 Jewett-Cameron Trad...
Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF) PR Newswire Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical,...